Morocco Targets $1.7 Bln in Non-Phosphate Mining Revenue by 2030

A man wearing a compulsory face mask observes his neighborhood from a hill during a health state of emergency and home confinement orders in Rabat, Morocco. (AP)
A man wearing a compulsory face mask observes his neighborhood from a hill during a health state of emergency and home confinement orders in Rabat, Morocco. (AP)
TT

Morocco Targets $1.7 Bln in Non-Phosphate Mining Revenue by 2030

A man wearing a compulsory face mask observes his neighborhood from a hill during a health state of emergency and home confinement orders in Rabat, Morocco. (AP)
A man wearing a compulsory face mask observes his neighborhood from a hill during a health state of emergency and home confinement orders in Rabat, Morocco. (AP)

Morocco plans to raise revenue from non-phosphate mining to more than 15 billion dirhams ($1.7 billion) by 2030 from 6.5 billion dirhams in 2020 by facilitating investments and tax incentives.

With 72% of global reserves, Morocco is the world’s largest phosphates exporter and last year its state-owned phosphates company OCP reported revenue of 56.1 billion dirhams.

The Moroccan energy and mining ministry said on Monday in its 2025-2030 mining development plan that it is also aiming for a tenfold increase in investment in mine prospecting and research to 4 billion dirhams.

It did not say which minerals it would target, but Energy and Mining Minister Aziz Rebbah told a news conference that the government would put particular focus on “strategic metals” such as those used in the renewable energy sector.

Morocco is a major producer of renewable energy but also relies on gas imports, including through a pipeline running from natural gas producer Algeria through Morocco to Spain.

However, it is at odds with Algeria over the Western Sahara and has recently had a dispute with Spain.

Rebbah declined to answer a question on whether Rabat planned to renew the pipeline deal, which expires in November, but said the pipeline was “strategic” to Morocco’s gas supply.



UAE’s Mubadala Acquires Majority Stakes in Global Medical Supply Chain, Al Ittihad Drug

The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
TT

UAE’s Mubadala Acquires Majority Stakes in Global Medical Supply Chain, Al Ittihad Drug

The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM

Mubadala Investment Company has acquired an 80% stake in Global Medical Supply Chain (GMSC) and Al Ittihad Drug Store (IDS) from GlobalOne Healthcare Holding (GHH), with GHH retaining a 20% stake, Emirates News Agency (WAM) reported on Tuesday.

This strategic acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors, aligning with the UAE's vision to establish a robust life sciences infrastructure, WAM said.

Founded in 2015, GMSC provides comprehensive end-to-end supply chain services for medical products, including demand planning, procurement, logistics, inventory management, warehousing, and maintenance.

GMSC serves over 200 medical facilities, including hospitals and clinics across the UAE. With a dedicated team of medical supply chain specialists, GMSC sources a broad array of products from almost 400 suppliers, ensuring a reliable supply chain for all medical needs.

IDS, established in 1987, stands as one of the leading distributors of pharmaceutical and consumer healthcare products in the UAE. Distributing over 1,000 products from over 40 leading suppliers, IDS services every hospital, and all, or at least most pharmacies and supermarkets within the UAE. It boasts a vast portfolio that spans multiple therapeutic categories including anti-infectives, asthma, diabetes, and oncology.

"The expanding pharmaceutical market drives an increasing demand for specialized and efficient drug logistics solutions. By integrating GMSC and IDS into our portfolio, we are poised to create a vertically integrated life sciences sector in the UAE and enable its potential to encompass the entire value chain from logistics and distribution to specialized manufacturing,” said Executive Director of UAE Clusters at Mubadala's UAE Investments Platform Ismail Ali Abdulla.

As for Low Ping, Group CEO Yas Holding, she said that the transaction “continues Mubadala's strategic growth, following another significant acquisition by its new speciality pharmaceutical business, KELIX bio, which recently acquired a 100% stake in four pharma assets from GlobalOne Healthcare Holding's, the healthcare division of Yas Holding.”

“These concerted efforts underline Mubadala's commitment to strengthening the UAE's healthcare and pharmaceutical sectors as part of broader national ambitions for drug security and economic diversification."

GlobalOne Healthcare Holding LLC serves as the dedicated Healthcare Division of Yas Holding LLC, focusing on enhancing healthcare outcomes by investing in innovative solutions across various healthcare verticals.